+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Glaucoma Therapeutics Market Report and Forecast 2023-2031

  • PDF Icon


  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797925
The global glaucoma therapeutics market value in 2022 was USD 6.6 billion driven by the increasing technological advancements in glaucoma diagnosis and treatment across the globe. The market size is anticipated to grow at a CAGR of 5.2% during the forecast period of 2023-2031 to achieve a value of USD 10.5 billion by 2031.

Glaucoma Therapeutics Introduction

Glaucoma is a condition that affects the eyes and can result in blindness. It is caused by high intraocular pressure that damages the optic nerve. Glaucoma therapeutics are drugs and treatments used to manage the condition and prevent further damage to the optic nerve.

The global glaucoma therapeutics market is expected to grow significantly due to the rising prevalence of glaucoma worldwide. The market is driven by the increasing aging population, technological advancements in glaucoma diagnosis and treatment, and growing awareness about glaucoma. The market is also influenced by the high cost of treatment and the lack of access to effective medications in some regions.

Key trends in the glaucoma therapeutics market include the development of new drug delivery methods such as sustained-release implants and the increasing use of combination therapies to improve treatment outcomes. There is also a growing interest in the use of cannabinoids for glaucoma treatment, as some studies have shown their potential in reducing intraocular pressure. Additionally, there is a focus on personalized medicine and the development of targeted therapies based on the individual patient's genetic makeup.

Glaucoma Therapeutics Market Scenario

Glaucoma is a group of eye diseases that damage the optic nerve, which is essential for healthy vision. It is the leading cause of irreversible blindness worldwide. Glaucoma therapeutics are drugs used for the treatment of glaucoma, which reduce intraocular pressure (IOP) and delay or prevent further optic nerve damage. The global glaucoma therapeutics market is driven by the rising prevalence of glaucoma and the growing geriatric population, which is more susceptible to the disease.

Additionally, technological advancements in the field of ophthalmology and the development of novel drug delivery systems are expected to drive the growth of the market. However, high costs associated with glaucoma therapeutics and the availability of alternative treatment options such as surgery and laser therapy are some of the major challenges faced by the market.

The market is expected to witness significant growth in the coming years due to the increasing demand for effective glaucoma therapeutics and the development of new drugs and therapies.

Glaucoma Therapeutics Market Segmentations

Market Breakup by Drug Class

  • Beta Blockers
  • Prostaglandins
  • Alpha Adrenergic Agonist
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

Market Breakup by Glaucoma Type

  • Closed Angle Glaucoma (CAG)
  • Open Angle Glaucoma (OAG)
  • Secondary Glaucoma
  • Congenital Glaucoma
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parentals
  • Topicals
  • Others

Market Breakup by Treatment Channel

  • Public
  • Private

Market Breakup by End User

  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada


  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Glaucoma Therapeutics Market

Some key trends in the Glaucoma Therapeutics market are:
  • Increased research and development: There is a significant increase in the research and development of new glaucoma drugs. Many pharmaceutical companies are investing in the development of novel therapies that provide better results with fewer side effects
  • Growing prevalence of glaucoma: The prevalence of glaucoma is growing globally, especially in the aging population. As a result, the demand for glaucoma therapeutics is expected to increase significantly in the coming years
  • Technological advancements: The glaucoma therapeutics market is witnessing significant technological advancements. For instance, the development of novel drug delivery systems such as sustained-release implants and nanotechnology-based drug delivery systems is expected to drive the market growth
  • Increasing awareness: The rising awareness among patients regarding the early diagnosis and treatment of glaucoma is likely to boost the market growth. Many initiatives and awareness programs are being conducted globally to educate people about the disease and its treatment options
  • Strategic collaborations: Many pharmaceutical companies are collaborating with other companies and academic institutions to develop innovative therapies and strengthen their market position. These collaborations are expected to drive the growth of the glaucoma therapeutics market

Glaucoma Therapeutics Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Aerie Pharmaceuticals, Inc
  • Allergan
  • Bausch Health
  • Merck & Co. Inc
  • Pfizer Inc
  • Fera Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd
  • EyePoint Pharmaceuticals
  • Amorphex Therapeutics LLC
  • Acorn Biomedical, Inc
  • Acucela Inc
  • Alcon
  • Astellas Pharma Inc
  • Bayer AG
  • BioAxone
  • Novartis AG
  • Carl Zeiss Meditec
  • Alcon, Lumenis
  • Topcon Medical Systems
  • Accutome

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Glaucoma Diseases Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Glaucoma Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Glaucoma Epidemiology (2016-2031)
5.3 Europe Glaucoma Epidemiology (2016-2031)
5.4 Asia-Pacific Glaucoma Epidemiology (2016-2031)
5.5 Latin America Glaucoma Epidemiology (2016-2031)
5.6 Middle East & Africa Glaucoma Epidemiology (2016-2031)
6 Global Glaucoma Therapeutics Market Overview
6.1 Global Glaucoma Therapeutics Market Historical Value (2016-2022)
6.2 Global Glaucoma Therapeutics Market Forecast Value (2023-2031)
7 Global Glaucoma Therapeutics Market Landscape
7.1 Glaucoma Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Glaucoma Therapeutics: Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by Glaucoma Type
7.2.3 Analysis by Route of Administration
7.2.4 Analysis by End User
7.2.5 Analysis by Distribution Channel
8 Glaucoma Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Glaucoma Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Glaucoma Therapeutics Market Segmentation
11.1 Global Glaucoma Therapeutics Market by Drug Class
11.1.1 Market Overview
11.1.2 Beta Blockers
11.1.3 Prostaglandins
11.1.4 Alpha Adrenergic Agonist
11.1.5 Carbonic Anhydrase Inhibitors
11.1.6 Combination Drugs
11.1.7 Others
11.2 Global Glaucoma Therapeutics Market by Glaucoma Type
11.2.1 Market Overview
11.2.2 Closed Angle Glaucoma (CAG)
11.2.3 Open Angle Glaucoma (OAG)
11.2.4 Secondary Glaucoma
11.2.5 Congenital Glaucoma
11.2.6 Others
11.3 Global Glaucoma Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parentals
11.3.4 Topicals
11.3.5 Others
11.4 Global Glaucoma Therapeutics Market by Treatment Channel
11.4.1 Market Overview
11.4.2 Public
11.4.3 Private
11.5 Global Glaucoma Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Specialty Clinics
11.5.4 Homecare Settings
11.5.5 Others
11.6 Global Glaucoma Therapeutics Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacy
11.6.3 Retail Pharmacy
11.6.4 Online Pharmacy
11.6.5 Others
11.7 Global Glaucoma Therapeutics Market by Region
11.7.1 Market Overview
11.7.2 North America
11.7.3 Europe
11.7.4 Asia Pacific
11.7.5 Latin America
11.7.6 Middle East and Africa
12 North America Glaucoma Therapeutics Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Glaucoma Therapeutics Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Glaucoma Therapeutics Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Glaucoma Therapeutics Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Glaucoma Therapeutics Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.5 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Grants Analysis
19.1 Analysis by year
19.2 Analysis by Amount Awarded
19.3 Analysis by Issuing Authority
19.4 Analysis by Grant Application
19.5 Analysis by Funding Institute
19.6 Analysis by NIH Departments
19.7 Analysis by Recipient Organization
20 Clinical Trials Analysis
20.1 Analysis by Trial Registration Year
20.2 Analysis by Trial Status
20.3 Analysis by Trial Phase
20.4 Analysis by Therapeutic Area
20.5 Analysis by Geography
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Partnership and Collaborations Analysis
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Aerie Pharmaceuticals, Inc.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Allergan
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Bausch Health
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Merck & Co. Inc.
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Pfizer Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 Fera Pharmaceuticals
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Teva Pharmaceutical Industries Ltd.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 EyePoint Pharmaceuticals
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Amorphex Therapeutics LLC.
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Acorn Biomedical, Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Acucela Inc.
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 Alcon
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 Astellas Pharma Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Bayer AG
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 BioAxone
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Novartis AG
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Carl Zeiss Meditec
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 Alcon, Lumenis
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Topcon Medical Systems
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Accutome
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
24 Glaucoma Therapeutics Market- Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • Aerie Pharmaceuticals, Inc.
  • Allergan
  • Bausch Health
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Fera Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Eyepoint Pharmaceuticals
  • Amorphex Therapeutics LLC.
  • Acorn Biomedical, Inc.
  • Acucela Inc.
  • Alcon
  • Astellas Pharma Inc.
  • Bayer AG
  • Bioaxone
  • Novartis AG
  • Carl Zeiss Meditec
  • Alcon, Lumenis
  • Topcon Medical Systems
  • Accutome



Table Information